Novel barrier products: synthesis design using controlled radical polymerization in dispersed systems. Personal barrier products (eg surgical and industrial rubber gloves) are currently manufactured using emulsion polymerization synthesis methods that have evolved little in 50 years. A dramatic new method for controlling polymer architecture, developed by a team led by the CI and Dulux for paints, also has the potential to tailor-make barrier products, from less hazardous raw materials. This pro ....Novel barrier products: synthesis design using controlled radical polymerization in dispersed systems. Personal barrier products (eg surgical and industrial rubber gloves) are currently manufactured using emulsion polymerization synthesis methods that have evolved little in 50 years. A dramatic new method for controlling polymer architecture, developed by a team led by the CI and Dulux for paints, also has the potential to tailor-make barrier products, from less hazardous raw materials. This project commences the fundamental research for understanding the mechanisms involved in using this method with butadiene, and the mechanical properties of the resulting novel block copolymers. This science would later be applied by the industrial partner to significantly improve their barrier products.Read moreRead less
Study the Utility of Novel Drug Polymer Conjugates. The products likely to arise from the technology described in this proposal could have application in medical, veterinary and agricultural industries. It offers the potential to treat diseases that are at present poorly treated by enabling delivery direct to the diseased organ (e.g. eye - bacterial endophthalmitis). Completion of the project will also assist a fledgling biotech company transition to a development company with a multiple produ ....Study the Utility of Novel Drug Polymer Conjugates. The products likely to arise from the technology described in this proposal could have application in medical, veterinary and agricultural industries. It offers the potential to treat diseases that are at present poorly treated by enabling delivery direct to the diseased organ (e.g. eye - bacterial endophthalmitis). Completion of the project will also assist a fledgling biotech company transition to a development company with a multiple product portfolio, which will have a direct economic benefit to Australia both in terms of potential export earnings and as an employer highly skilled staff. The project will also provide research training and career opportunities for developing Australian based researchers.Read moreRead less